MOG-Peptide Synergizes with Rapamycin to Drive CD4 T Cells Into Protective Antigen-Specific Tregs in EAE

Researchers investigated whether rapamycin, a well-characterized mTOR inhibitor known to favour differentiation and metabolic reprogramming of Tregs, could synergize with MOG35-55-peptide to convert naïve T cells into protective, MOG35-55-specific Tregs.